Is Suven Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Suven Pharmaceuticals Ltd is a good quality company .

Is Suven Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Suven Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Suven Pharmaceuticals share price return in the past 10 years?

Data is not available for this company

Is Suven Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Suven Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Suven Pharmaceuticals?

The latest standalone P/E ratio of Suven Pharmaceuticals as of 20-Dec-2024 is 121.61.

What is the P/B ratio of Suven Pharmaceuticals?

The latest standalone P/B ratio of Suven Pharmaceuticals as of 20-Dec-2024 is 13.63.

What is the 52-week high and low of Suven Pharmaceuticals?

The 52-week high of Suven Pharmaceuticals is Rs. 1359.00 and the 52-week low is Rs. 586.10.

Suven Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Suven Pharmaceuticals
Brand: Suven Pharmaceuticals

BSE: 543064 | NSE: SUVENPHAR | Pharmaceuticals & Drugs | Small Cap

Place order

Suven Pharma Share Price

₹1,180.90 -37.40 -3.07%
as on 20-Dec'24 16:59

10 Year X-Ray of Suven Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0%	0%	0%	0%	23.9%	50.2%	40.8%	45.9%	33.4%	21.2%	-
Value Creation Index ⓘ	NA	NA	NA	NA	1.1	3.5	2.0	2.4	1.5	0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	0	378	834	1,010	1,320	1,340	1,051	961
Sales YoY Gr.	-	NA	NA	NA	NA	120.7%	21.1%	30.8%	1.5%	-21.6%	-
Adj EPS ⓘ	0	0	0	0	0	12	13.9	15.3	15.1	10.3	9.6
YoY Gr.	-	NA	NA	NA	NA	NA	15.9%	10.5%	-1.2%	-31.7%	-
BVPS (₹) ⓘ	0	0	0	0	0	33.2	46.4	60	68.2	80.5	77.7
Adj Net Profit ⓘ	0	0	0	0	111	305	353	390	385	263	243
Cash Flow from Ops. ⓘ	0	0	0	0	50.4	407	383	330	457	358	-
Debt/CF from Ops. ⓘ	0	0	0	0	1.6	0.5	0.4	0.3	0.2	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	22.7%	1.4%	-21.6%
Adj EPS ⓘ	NA	NA	-9.4%	-31.7%
BVPSⓘ	NA	NA	20.2%	18.1%
Share Price	-	-	35.1%	75.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	18.8	42.5	34.9	28.8	23.6	13.9	12.1
Op. Profit Mgn % ⓘ	46.1	46.2	43.9	44.1	42.8	38.6	33.6
Net Profit Mgn % ⓘ	29.4	36.6	35	29.6	28.8	25	25.3
Debt to Equity ⓘ	0.1	0.2	0.1	0.1	0	0	0
Working Cap Days ⓘ	0	196	175	172	195	213	214
Cash Conv. Cycle ⓘ	0	81	57	69	89	104	184

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 12.10%

Sales growth has been subdued in last 3 years 1.36%

Net Profit has been subdued in last 3 years -9.35%

Sales growth is not so good in last 4 quarters at -22.87%

Latest Financials - Suven Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	9.7	9.6
TTM Sales (₹ Cr.)	915	961
BVPS (₹.) ⓘ	86.7	77.7
Reserves (₹ Cr.) ⓘ	2,170	1,953
P/BV ⓘ	13.63	15.20
PE ⓘ	121.61	123.66

From the Market
52 Week Low / High (₹)	586.10 / 1359.00
All Time Low / High (₹)	87.05 / 1359.00
Market Cap (₹ Cr.)	30,062
Equity (₹ Cr.)	25.5
Face Value (₹)	1
Industry PE ⓘ	44.3

Management X-Ray of Suven Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Suven Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Suven Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	378	834	1,010	1,320	1,340	1,051
Operating Expenses ⓘ	206	449	567	739	766	646
Manufacturing Costs	53	122	150	189	184	137
Material Costs	101	225	298	394	403	311
Employee Cost	30	65	76	100	118	136
Other Costs ⓘ	22	36	43	55	61	61
Operating Profit ⓘ	172	385	443	582	574	406
Operating Profit Margin (%)	45.4%	46.1%	43.9%	44.1%	42.8%	38.6%
Other Income ⓘ	1	18	14	92	46	62
Interest ⓘ	3	23	12	9	13	7
Depreciation ⓘ	11	24	32	39	48	55
Exceptional Items ⓘ	0	0	0	0	0	0
Profit Before Tax ⓘ	158	405	468	668	560	406
Tax ⓘ	49	88	105	214	148	105
Profit After Tax	109	317	362	454	411	300
PAT Margin (%)	28.9%	38.0%	35.9%	34.4%	30.7%	28.6%
Adjusted EPS (₹)	0.0	12.5	14.2	17.8	16.2	11.8
Dividend Payout Ratio (%)	0%	20%	14%	28%	37%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	578	845	1,181	1,527	1,735	2,049
Share Capital ⓘ	0	13	25	25	25	25
Reserves ⓘ	578	832	1,155	1,502	1,710	2,023
Minority Interest	0	0	0	0	0	0
Debt	83	185	141	96	69	39
Long Term Debt	0	91	36	28	5	0
Short Term Debt	83	94	106	67	65	39
Trade Payables	54	71	83	106	70	42
Others Liabilities ⓘ	102	191	171	238	236	224
Total Liabilities ⓘ	816	1,292	1,576	1,967	2,110	2,353
Fixed Assets
Gross Block	347	457	570	694	876	927
Accumulated Depreciation	77	100	128	160	212	258
Net Fixed Assetsⓘ	271	357	441	534	663	670
CWIP ⓘ	111	102	96	30	165	179
Investmentsⓘ	7	338	542	598	536	904
Inventories	157	175	201	283	313	231
Trade Receivables	148	117	102	236	111	134
Cash Equivalents	13	14	10	47	68	50
Others Assetsⓘ	109	190	184	237	254	185
Total Assets ⓘ	816	1,292	1,576	1,967	2,110	2,353

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	50	407	383	330	457	358
PBT ⓘ	158	405	468	668	560	406
Adjustment ⓘ	14	35	36	41	37	15
Changes in Working Capital ⓘ	-88	54	-12	-194	6	47
Tax Paid ⓘ	-33	-86	-109	-184	-146	-110
Cash Flow From Investing Activity ⓘ	-65	-413	-311	-136	-195	-362
Capex	-57	-103	-111	-75	-286	-52
Net Investments	-7	-325	-201	-300	84	-312
Others ⓘ	-2	15	0	239	6	2
Cash Flow From Financing Activityⓘ	26	7	-76	-156	-242	-14
Net Proceeds from Shares ⓘ	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	52	91	-55	-10	-24	-5
Interest Paid ⓘ	-3	-17	-9	-6	-12	-7
Dividend Paid ⓘ	-19	-64	-25	-102	-204	0
Others ⓘ	-4	-3	13	-39	-3	-2
Net Cash Flow ⓘ	11	1	-5	37	20	-18

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	18.92	44.58	35.78	33.52	25.21	15.87
ROCE (%)	23.87	50.21	40.76	45.92	33.41	21.22
Asset Turnover Ratio	0.46	0.79	0.7	0.75	0.66	0.47
PAT to CFO Conversion(x)	0.46	1.28	1.06	0.73	1.11	1.19
Working Capital Days
Receivable Days	142	58	40	47	47	42
Inventory Days	152	73	68	67	81	94
Payable Days	193	101	94	87	80	66

Suven Pharmaceuticals Ltd Stock News

Suven Pharmaceuticals Ltd FAQs

What is the share price of Suven Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Suven Pharma on 20-Dec-2024 16:59 is ₹1,180.9.

What is the market cap of Suven Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Suven Pharma stood at ₹30,061.6.

What is the P/E ratio of Suven Pharma?

The latest P/E ratio of Suven Pharma as of 20-Dec-2024 16:59 is 121.6.

What is the P/B ratio of Suven Pharma?

The latest P/B ratio of Suven Pharma as of 20-Dec-2024 16:59 is 13.63.

What is the 52-week high and low of Suven Pharma?

The 52-week high of Suven Pharma is ₹1,359 and the 52-week low is ₹586.1.

What is the TTM revenue of Suven Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Suven Pharma is ₹914.5 ( Cr.) .

About Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020.

Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement.

The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company.

Business area of the company

The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

Business segments